Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aimmune Therap (NQ: AIMT )

34.49 USD UNCHANGED
Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Aimmune Therap

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags APYX NGM HZNP
From Benzinga
Aimmune Therapeu Shares Down 5.2% Since SmarTrend's Sell Call (AIMT)
SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on March 20th, 2019 at $21.45. In approximately 1 month, Aimmune Therapeu has returned 5.22% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio
Here's a roundup of top developments in the biotech space over the last 24 hours: No biotech stocks hit 52-week highs on ... 
Tags UMRX ACRS Benzinga
From Benzinga
Top Buys by Top Brass: CEO Dallas's $100.6K Bet on AIMT
A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider... 
Tags Stocks
From Market News Video
Aimmune Therapeu Bearish Moving Average Crossover Alert (AIMT)
Today, shares of Aimmune Therapeu (NASDAQ:AIMT) have crossed bearishly below their 10-day moving average of $22.57 on a volume of 107K shares. This may provide swing traders with an... 
From Comtex SmarTrend® News Briefs
We Did The Math XBI Can Go To $128
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
4 Blockbuster Drug Launches to Watch in 2019
These four experimental drugs will reach the market soon, and the companies launching them have little room for error. 
Tags Market News ABBV ALXN
From Motley Fool
The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags News Pre/Market Outlook PTLA
From Benzinga
Add Up The Pieces: JKJ Could Be Worth $189
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Land Shares of AIMT 12.8% Cheaper Than the CEO Did
There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 19, Aimmune Therapeutics Inc's CEO, Jayson... 
Tags Stocks
From Market News Video
The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting ... 
Tags HBIO XBI CHRS
From Benzinga
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
Biotech stocks came under pressure in the week ending Feb. 22 after advancing in the previous week. The recent week was fairly quiet for ... 
Tags SYN BMY Health Care
From Benzinga
First Week of April 18th Options Trading For Aimmune Therapeutics
Investors in Aimmune Therapeutics Inc (AIMT) saw new options become available this week, for the April 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT... 
Tags Stocks
From Market News Video
DBV Jumps 41% To $9.96 After Update On Viaskin Peanut Filing
Shares of DBV Technologies jumped after the company said that its planned resubmission of the Biologics License Application to the FDA for Viaskin Peanut is anticipated in the third quarter of 2019. 
Tags Healthcare Stocks / Equities
From Blogs - TalkMarkets
Battered biotech behind buzzy peanut-allergy therapy says it’s ready to move forward
Shares of DBV Technologies took a beating in December, when the biotech withdrew its marketing application for a peanut allergy therapy. 
Tags AIMT Health/Care Medical Products
From MarketWatch
Analysts Expect ESML Will Reach $29
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
6 Biotech Stocks to Watch Now
Here are six stocks that could pop or drop in 2019 based on these fast-approaching catalysts. 
Tags BLUE AIMT SRPT
From Motley Fool
3 Top Biotech Stocks to Buy Right Now
Biotech may be a tough industry to invest in, but we've found three companies within that space that are worth looking into. 
Tags REGN Market News AIMT
From Motley Fool
Short-term budget deal comes just in time for biotech firms
Initial public offerings and drug approvals had been held up by the partial government shutdown. 
Tags Biotechnology Health Care/Pharmaceuticals Biotechnology and Life Sciences Aimmune Therapeutics Inc
From CNBC.com News
3 Biotech Stocks That Could Be Slapped by the U.S. Government Shutdown
No funding for the FDA means delays in drug reviews and approvals. And that could translate to bad news for these three biotechs. 
Tags Market News AMRN CELG
From Motley Fool
Week In Review: How Trump's Policies Moved Stocks - Jan. 20
Companies begin to see impact from shutdown, Grassley sees Trump proceeding with tariffs on imported cars 
From Blogs - TalkMarkets
3 Potential New Drugs Held Up by the Shutdown
The market's about to find out the FDA does a lot more than check lettuce. 
Tags CELG BMY AIMT
From Motley Fool
How the government shutdown is affecting biotech companies
The government shutdown is affecting the U.S. Food and Drug Administration’s ability to review new drugs, putting biotech companies in a tough spot. 
Tags AGIO INCY Health/Care
From MarketWatch
Hundreds of FDA staff return to work amid shutdown -Commissioner
About 400 U.S. Food and Drug Administration staffers have returned to their posts from furlough, including some food inspectors and support professionals, Commissioner Scott Gottlieb said in a tweet on... 
Tags companyNews
From Reuters: Company News
Jim Cramer Shares His Thoughts On Alibaba, Dynavax, Starbucks And More
On CNBC's "Mad Money Lightning Round", Jim Cramer said Dynavax Technologies Corporation (NASDAQ: DVAX) is too low to sell, ... 
Tags IDXX Benzinga CNBC
From Benzinga
Cramer's lightning round: The way to play Goldman's downgrade of Starbucks
Jim Cramer zips through his responses to callers' stock questions, including one on a high-profile coffee play. 
Tags Business Mad Money ArcelorMittal SA
From CNBC.com News
A Peek Into The Markets: US Stock Futures Down Ahead Of Economic Data
Pre-open movers U.S. stock futures traded lower in early pre-market trade. The ISM non-manufacturing index for December and data on ... 
Tags ADBE Market News US Stock Futures
From Benzinga
5 Stocks To Watch For January 7, 2019
Some of the stocks that may grab investor focus today are: KKR & Co Inc (NYSE: KKR) entered into a loan agreement with Aimmune ... 
Tags Market News Stocks To Watch Markets
From Benzinga
February 2019 Options Now Available For Aimmune Therapeutics (AIMT)
Investors in Aimmune Therapeutics Inc (AIMT) saw new options begin trading today, for the February 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT... 
Tags Stocks
From Market News Video
60 Biggest Movers From Yesterday
Gainers Inpixon (NASDAQ: INPX) shares climbed 37.12 percent to close at $4.10 on Thursday after the company announced it is on ... 
Tags Market News TLRY MRKR
From Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback